Amphastar Pharmaceuticals Inc vs Materials Select Sector SPDR Fund — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while Materials Select Sector SPDR Fund trades at $50.79. The key difference: Materials Select Sector SPDR Fund is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | XLB | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | — |
52-Week High | $30.81 | $53.62 |
52-Week Low | $16.87 | $42.23 |
Enterprise Value | $1.22B | — |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
XLB, the State Street Materials Select Sector SPDR ETF, trades at $50.89 with a 1.21% daily gain. Technical indicators signal a bearish trend with moving averages showing sell pressure, while oscillators remain neutral. Recent news highlights materials sector capital inflows and geopolitical impacts on supply chains. The ETF provides diversified exposure to U.S. materials companies, with a dividend scheduled for June 2026.
Outlook remains cautious due to bearish technicals and geopolitical sensitivity. Investment appeal hinges on sector earnings growth potential amid inflation and supply disruptions. Key risks include macroeconomic volatility and concentrated sector exposure, requiring careful risk assessment for equity investors.
Trailing returns across standard periods
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →